Skyhawk Advances SKY-0515 Phase 1 Study to Multiple Ascending Dose for Huntington's Disease Treatment

Skyhawk Therapeutics has made significant progress with its innovative drug candidate, SKY-0515, which is engineered to be an RNA splicing modifier. The compound has now moved into the multiple ascending dose phase of its Phase 1 clinical trial, following its successful single ascending dose phase. This advancement is particularly noteworthy as it targets Huntington's disease (HD), a devastating neurological condition for which there are currently no curative treatments available.
The Phase 1 clinical study of SKY-0515 is being conducted in Australia and is aimed at assessing the safety and efficacy of the drug in modifying the RNA expression of the huntingtin (HTT) gene, which is responsible for the production of the mutated protein associated with HD. The drug candidate is designed to reduce this protein's production, potentially slowing or reversing the disease's progression. Douglas Faller, the Chief Medical Officer at Skyhawk Therapeutics, expressed optimism about the drug's preclinical performance and its potential to benefit patients.
In the United States, there are around 30,000 individuals who are symptomatic of HD, with many more being pre-symptomatic. The SKY-0515 drug is taken orally, targets HTT RNA directly, and is capable of penetrating the brain and distributing to peripheral tissues, which could offer significant advantages for patients. Notably, this is the first drug developed by Skyhawk to reach the clinical trial stage.
The Phase 1 trial of SKY-0515 is a complex study involving both healthy volunteers and HD patients, focusing on the drug's safety, tolerability, pharmacokinetics, and pharmacodynamic activity. More details about the trial are available on the Australian New Zealand Clinical Trials Registry.
Huntington's disease is a genetic disorder that leads to the gradual deterioration of brain cells, affecting movement, cognition, and mental health, and is invariably fatal. The disease typically manifests in mid-adulthood, and while there are medications to manage symptoms, no treatment currently exists to cure or halt the disease's progression.
Skyhawk Therapeutics utilizes its proprietary SKYSTAR® platform to develop therapies that alter RNA expression, aiming to offer significant advancements in patient care across various disease areas, including neurodegenerative diseases and cancer. The company is dedicated to forging collaborations to expand its therapeutic reach. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!